2024-02-02 10:58:27 ET
Summary
- Primary endpoint met of HAM-A scores at week 4 met in phase 2b MMED008 study, when Generalized Anxiety Disorder patients were given MM-120.
- 12-week HAM-A results from phase 2b MMED008 study in GAD to be released end of Q1 of 2024 with full data set at upcoming medical meeting in 2024.
- End of phase 2 meeting with FDA to discuss advancement of MM-120 for GAD expected in the 1st half of 2024; Phase 3 trial initiation expected 2nd half of 2024.
- The generalized anxiety disorder market size is estimated to reach $8.1 billion by 2027.
The last time I spoke about Mind Medicine ( MNMD ) it was gearing up to report results from its phase 2b trial using its lead drug MM-120 for the treatment of patients with generalized anxiety disorder [GAD]. I wrote about this in a Seeking Alpha article entitled " Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look ". I'm happy to report that since I wrote this article it was able to achieve this trial's primary endpoint of the drug being able to demonstrate a statistically significant dose-dependent improvement in HAM-A scores 4 weeks after a single dose. The reason why I believe that further value can be unlocked here is because this positive outcome from this mid-stage study, leads to several other catalysts to look forward to in 2024....
Read the full article on Seeking Alpha
For further details see:
Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts